EWTX | Ticker Profile - Titan Protect

EWTX

Edgewise Therapeutics, Inc.

Healthcare · Biotechnology · NMS

$35.59

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$3.6B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-14.38

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-38.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$45.50

+28% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 12 analysts covering this stock

About Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

https://edgewisetx.com

Country: United States Employees: 154 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.789

Good returns relative to risk taken

Kelly Fraction

0.0718

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.573

Acceptable balance between returns and drawdown risk

Annual Return

39.4%

Historical annualised return based on price data

Max Drawdown

-68.8%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.25

Very low correlation to market moves

52W High

$39.96

11% below the year high

52W Low

$12.15

193% above the year low

Avg Volume

1,035,021

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

13.6%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.66

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.77

Moderate leverage — manageable

Current Ratio

22.61

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

22.16

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-90,515,248

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-176,010,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$52.00

Target Median

$45.50

Target Low

$20.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go